Edoxaban for the Long-Term Therapy of Venous Thromboembolism : Should the Criteria for Dose Reduction be Revised?
Camporese, Giuseppe (University Hospital of Padova (Pàdua, Itàlia))
Simioni, Paolo (University Hospital of Padova (Pàdua, Itàlia))
Di Micco, Pierpaolo (Ospedale Buon Consiglio Fatebenefratelli (Nàpols, Itàlia))
Fernández-Capitán, Carmen (Hospital Universitario La Paz (Madrid))
Rivas, Agustina (Arabako Unibertsitate Ospitalea (Vitoria, País Basc))
Font, C (Hospital Clínic i Provincial de Barcelona)
Sahuquillo, Joan Carles (Hospital Municipal de Badalona)
Villares, Paula (Hospital Universitario HM Sanchinarro (Madrid))
Prandoni, Paolo (University of Padua)
Monreal, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Fecha:	2020
Resumen:	Edoxaban is used for venous thromboembolism (VTE) treatment. Real-life data are lacking about its use in long-term therapy. We aimed to assess the efficacy and the safety of edoxaban for long-term VTE treatment in a real-life setting. Patients with VTE included in the egistro nformatizado nfermedad rombombólica (RIETE) registry, receiving edoxaban 60 or 30 mg daily were prospectively followed up to validate the benefit of using different dosages. The main outcome was the composite of VTE recurrences or major bleeding in patients with or without criteria for dose reduction. Multivariable analysis to identify predictors for the composite outcome was performed. From October 2015 to November 2019, 562 patients received edoxaban for long-term therapy. Most (94%) of the 416 patients not meeting criteria for dose reduction received 60 mg daily, and 92 patients meeting criteria (63%) received 30 mg daily. During treatment, two patients developed recurrent VTE, six had major bleeding and nine died (2 from fatal bleeding). Among patients not meeting criteria for dose reduction, those receiving 30 mg daily had a higher rate of the composite event (hazard ratio (HR) 8. 37; 95% confidence interval (CI) 1. 12-42. 4) and a significant higher mortality rate (HR 31. 1; 95% CI 4. 63-262) than those receiving 60 mg. Among patients meeting criteria for dose reduction, those receiving 60 mg daily had no events, and a nonsignificantly higher mortality rate (HR 5. 04; 95% CI 0. 54-133) than those receiving 30 mg daily. In conclusion, edoxaban seems to be effective and safe for long-term VTE treatment in real life. Criteria for dose reduction should be reformulated.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	Clinical and Translational Science, Vol. 14 (october 2020) , p. 335-342, ISSN 1752-8062

DOI: 10.1111/cts.12876
PMID: 33038286

8 p, 205.5 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados